AKT1 and thyroid cancer: Further experiments found that DSF/Cu sensitizes BRAF-mutated thyroid cancer cells to PLX4032 by suppressing the reactivation of HER3 caused by PLX4032, thereby blocking MAPK and PI3K/AKT pathways, and NAC could reverse this effect.